Neuropeptide Y Levels in Children and Adolescents with Attention Deficit Hyperactivity Disorder.
CONCLUSION: This study demonstrated that the NPY levels of ADHD subjects were not different than those of controls. Future studies with homogeneous phenotypes and a larger sample population are needed. PMID: 29730872 [PubMed - in process]
CONCLUSIONS Our findings showed that about 20% of the youths had at least one mental disorder. However, this prevalence is underestimated since other relevant mental disorders were not assessed. Mental disorders were associated with higher suicide risk, especially the comorbidity between them.
In conclusion, CWE seem to benefit from interventions and behavior modification techniques first developed for children with ADHD.
In Reply We thank Cui and Liu as well as Dravland for their thoughtful comments about our work. Cui and Liu point out that we did not include a Chinese study by Zheng et al. This omission is unfortunate because it would have partly balanced the overrepresentation of North American data. The study is interesting because although in a cohort of 153 children aged 6 to 12 years the chosen dose range for titration of osmotic-release oral system methylphenidate (OROS-MPH) was 18 to 54 mg/d, after 12 weeks, the mean titrated dose was only 22.8 mg/d, and there were no children receiving 54 mg. Whether this reflects differences in ...
This article reports on 11 randomized clinical trials including 1304 participants treated with methylphenidate and 887 control individuals and 38 cohort studies including 5524 participants. The evidence from this meta-analysis showed that a range of maximum doses for methylphenidate was recommended in different clinical studies and no discernable scientific justification for any particular dose was offered. This meta-analysis is an advanced study to summarize and compare findings from clinical studies. However, there might be some limitations in this study.
Conclusions: Children with ADHD may suffer from sleep breathing problems and daytime sleepiness, as reported by their parents, even when their total sleep time and sleep efficiency are not affected. It seems that sleep in this population does not largely vary as a function of the ADHD presentation. Sleep in children with ADHD evolves with age.ResumenAntecedentes/ObjetivoExaminar los patrones de sueño subjetivos y objetivos de niños con diferentes presentaciones del Trastorno por déficit de atención e hiperactividad (TDAH). Método: Se evaluaron 92 niños (29 TDAH-inatento [TDAH-I)], ...
Psychostimulants are one of the safest and most efficacious pharmacological interventions for a psychiatric disorder. In 1999 the groundbreaking Multimodal Treatment of ADHD (MTA) study set the standard of care for long-term treatment for children with attention-deficit/hyperactivity disorder (ADHD).1 Since then, stimulant use has increased substantially around the world.2 Because ADHD is a chronic condition, guidelines recommend re-evaluating the continued use of stimulant medications over many years in order to assess symptom relief and associated poor academic, social and work-life functioning.
Molecular Psychiatry, Published online: 18 October 2019; doi:10.1038/s41380-019-0540-zDruggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment
We examined bidirectional relations between attention-deficit/hyperactivity disorder (ADHD) symptoms and family and school climate, and the possible role ofDRD4 and/or5-HTTLPR genotypes herein. Three-wave longitudinal data of 1860 adolescents (mean ages 11, 13.5, and 16 years) from the general population and clinic-referred cohort of TRacking Adolescents’ Individual Lives Survey were used. Using a multigroup Random Intercept Cross-Lagged Panel Model, we tested between-person (i.e., stable trait levels) and within-person (i.e., causal processes) associations acr oss ADHD symptoms, family and school climate, and ...
PMID: 31625498 [PubMed - as supplied by publisher]
This article aims to provide practical considerations for the management of ADHD and associated disorders in adults, in this particular French context. PMID: 31610922 [PubMed - as supplied by publisher]